MARIPOSA-2 Phase 3 Study Design and Treatment Arms

Opinion
Video

This segment discusses the details of the phase 3 randomized MARIPOSA-2 trial design evaluating amivantamab plus chemotherapy vs amivantamab, lazertinib and chemotherapy vs chemotherapy alone in osimertinib-resistant EGFR-mutant NSCLC.

ON-AMI BTL_Seg02
Video Player is loading.
Current Time 0:00
Duration 3:54
Loaded: 0%
Stream Type LIVE
Remaining Time 3:54
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    •What are your thoughts regarding the efficacy outcomes observed in MARIPOSA-2?•How did efficacy endpoints compare to the chemotherapy arm?

    Related Content